{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:56:32Z","timestamp":1793372192298,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1038\/s41401-021-00786-2","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T14:49:14Z","timestamp":1634309354000},"page":"1473-1483","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21\/FGFR1 signaling pathway"],"prefix":"10.1038","volume":"43","author":[{"given":"Yi-kuan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-nan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-long","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-zhou","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-long","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-xiao","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"key":"786_CR1","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1001\/jama.2015.5370","volume":"313","author":"ME Rinella","year":"2015","unstructured":"Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263\u201373.","journal-title":"JAMA."},{"key":"786_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/srep24399","volume":"6","author":"G Yang","year":"2016","unstructured":"Yang G, Lee HE, Lee JY. A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet. Sci Rep. 2016;6:24399.","journal-title":"Sci Rep"},{"key":"786_CR3","first-page":"284","volume":"3","author":"HR Yao","year":"2011","unstructured":"Yao HR, Liu J, Plumeri D, Cao YB, He T, Lin L, et al. Lipotoxicity in HepG2 cells triggered by free fatty acids. Am J Transl Res. 2011;3:284\u201391.","journal-title":"Am J Transl Res"},{"key":"786_CR4","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","volume":"52","author":"H Tilg","year":"2010","unstructured":"Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52:1836\u201346.","journal-title":"Hepatology."},{"key":"786_CR5","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1053\/j.gastro.2017.01.015","volume":"152","author":"C Alonso","year":"2017","unstructured":"Alonso C, Fernandez-Ramos D, Varela-Rey M, Martinez-Arranz I, Navasa N, Van Liempd SM, et al. Metabolomic identification of subtypes of nonalcoholic steatohepatitis. Gastroenterology. 2017;152:1449\u201361 e7.","journal-title":"Gastroenterology."},{"key":"786_CR6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nrd3739","volume":"11","author":"MO Dietrich","year":"2012","unstructured":"Dietrich MO, Horvath TL. Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. Nat Rev Drug Discov. 2012;11:675\u201391.","journal-title":"Nat Rev Drug Discov"},{"key":"786_CR7","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675\u201385.","journal-title":"N Engl J Med"},{"key":"786_CR8","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1463-1326.2011.01403.x","volume":"13","author":"JK Dowman","year":"2011","unstructured":"Dowman JK, Armstrong MJ, Tomlinson JW, Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes Obes Metab. 2011;13:692\u2013702.","journal-title":"Diabetes Obes Metab"},{"key":"786_CR9","doi-asserted-by":"publisher","first-page":"12457","DOI":"10.3748\/wjg.v21.i43.12457","volume":"21","author":"M Kikuchi","year":"2015","unstructured":"Kikuchi M, Ushida Y, Shiozawa H, Umeda R, Tsuruya K, Aoki Y, et al. Sulforaphane-rich broccoli sprout extract improves hepatic abnormalities in male subjects. World J Gastroenterol. 2015;21:12457\u201367.","journal-title":"World J Gastroenterol"},{"key":"786_CR10","doi-asserted-by":"crossref","first-page":"5438179","DOI":"10.1155\/2018\/5438179","volume":"2018","author":"X Su","year":"2018","unstructured":"Su X, Jiang X, Meng L, Dong X, Shen Y, Xin Y. Anticancer activity of sulforaphane: the epigenetic mechanisms and the Nrf2 signaling pathway. Oxid Med Cell Longev. 2018;2018:5438179.","journal-title":"Oxid Med Cell Longev"},{"key":"786_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jnutbio.2013.10.007","volume":"25","author":"KM Choi","year":"2014","unstructured":"Choi KM, Lee YS, Kim W, Kim SJ, Shin KO, Yu JY, et al. Sulforaphane attenuates obesity by inhibiting adipogenesis and activating the AMPK pathway in obese mice. J Nutr Biochem. 2014;25:201\u20137.","journal-title":"J Nutr Biochem"},{"key":"786_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.bbagen.2013.09.018","volume":"1840","author":"R Zhou","year":"2014","unstructured":"Zhou R, Lin J, Wu D. Sulforaphane induces Nrf2 and protects against CYP2E1-dependent binge alcohol-induced liver steatosis. Biochimica et biophysica acta. 2014;1840:209\u201318.","journal-title":"Biochimica et biophysica acta"},{"key":"786_CR13","doi-asserted-by":"publisher","first-page":"eaah4477","DOI":"10.1126\/scitranslmed.aah4477","volume":"9","author":"AS Axelsson","year":"2017","unstructured":"Axelsson AS, Tubbs E, Mecham B, Chacko S, Nenonen HA, Tang Y, et al. Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes. Sci Transl Med. 2017;9:eaah4477.","journal-title":"Sci Transl Med"},{"key":"786_CR14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3109\/09637486.2012.665043","volume":"63","author":"Z Bahadoran","year":"2012","unstructured":"Bahadoran Z, Tohidi M, Nazeri P, Mehran M, Azizi F, Mirmiran P. Effect of broccoli sprouts on insulin resistance in type 2 diabetic patients: a randomized double-blind clinical trial. Int J food Sci Nutr. 2012;63:767\u201371.","journal-title":"Int J food Sci Nutr"},{"key":"786_CR15","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.2337\/db11-0112","volume":"60","author":"DV Chartoumpekis","year":"2011","unstructured":"Chartoumpekis DV, Ziros PG, Psyrogiannis AI, Papavassiliou AG, Kyriazopoulou VE, Sykiotis GP, et al. Nrf2 represses FGF21 during long-term high-fat diet-induced obesity in mice. Diabetes. 2011;60:2465\u201373.","journal-title":"Diabetes."},{"key":"786_CR16","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.2337\/db11-1716","volume":"61","author":"J Xu","year":"2012","unstructured":"Xu J, Kulkarni SR, Donepudi AC, More VR, Slitt AL. Enhanced Nrf2 activity worsens insulin resistance, impairs lipid accumulation in adipose tissue, and increases hepatic steatosis in leptin-deficient mice. Diabetes. 2012;61:3208\u201318.","journal-title":"Diabetes."},{"key":"786_CR17","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.2337\/db14-0595","volume":"63","author":"KR Markan","year":"2014","unstructured":"Markan KR, Naber MC, Ameka MK, Anderegg MD, Mangelsdorf DJ, Kliewer SA, et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes. 2014;63:4057\u201363.","journal-title":"Diabetes."},{"key":"786_CR18","doi-asserted-by":"publisher","first-page":"12983","DOI":"10.1074\/jbc.M110.215889","volume":"286","author":"E Hondares","year":"2011","unstructured":"Hondares E, Iglesias R, Giralt A, Gonzalez FJ, Giralt M, Mampel T, et al. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem. 2011;286:12983\u201390.","journal-title":"J Biol Chem"},{"key":"786_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1101\/gad.177857.111","volume":"26","author":"FM Fisher","year":"2012","unstructured":"Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, Verdeguer F, et al. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 2012;26:271\u201381.","journal-title":"Genes Dev"},{"key":"786_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.molmet.2013.05.005","volume":"2","author":"AC Adams","year":"2013","unstructured":"Adams AC, Coskun T, Cheng CC, O Farrell LS, Dubois SL, Kharitonenkov A. Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones. Mol Metab. 2013;2:205\u201314.","journal-title":"Mol Metab"},{"key":"786_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1042\/BJ20140403","volume":"463","author":"F Ribas","year":"2014","unstructured":"Ribas F, Villarroya J, Hondares E, Giralt M, Villarroya F. FGF21 expression and release in muscle cells: involvement of MyoD and regulation by mitochondria-driven signalling. Biochem J. 2014;463:191\u20139.","journal-title":"Biochem J"},{"key":"786_CR22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2337\/db08-0392","volume":"58","author":"J Xu","year":"2009","unstructured":"Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009;58:250\u20139.","journal-title":"Diabetes."},{"key":"786_CR23","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI23606","volume":"115","author":"A Kharitonenkov","year":"2005","unstructured":"Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115:1627\u201335.","journal-title":"J Clin Invest"},{"key":"786_CR24","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1210\/en.2009-0532","volume":"150","author":"MK Badman","year":"2009","unstructured":"Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology. 2009;150:4931\u201340.","journal-title":"Endocrinology."},{"key":"786_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1124\/mol.108.044826","volume":"74","author":"ES Muise","year":"2008","unstructured":"Muise ES, Azzolina B, Kuo DW, El-Sherbeini M, Tan Y, Yuan X, et al. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol Pharmacol. 2008;74:403\u201312.","journal-title":"Mol Pharmacol"},{"key":"786_CR26","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.2337\/db07-1476","volume":"57","author":"X Zhang","year":"2008","unstructured":"Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008;57:1246\u201353.","journal-title":"Diabetes."},{"key":"786_CR27","doi-asserted-by":"publisher","first-page":"E1197","DOI":"10.1152\/ajpendo.00357.2009","volume":"297","author":"MK Badman","year":"2009","unstructured":"Badman MK, Kennedy AR, Adams AC, Pissios P, Maratos-Flier E. A very low carbohydrate ketogenic diet improves glucose tolerance in ob\/ob mice independently of weight loss. Am J Physiol Endocrinol Metab. 2009;297:E1197\u2013204.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"786_CR28","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1210\/jc.2008-0746","volume":"93","author":"I Dostalova","year":"2008","unstructured":"Dostalova I, Kavalkova P, Haluzikova D, Lacinova Z, Mraz M, Papezova H, et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab. 2008;93:3627\u201332.","journal-title":"J Clin Endocrinol Metab"},{"key":"786_CR29","doi-asserted-by":"publisher","first-page":"e24895","DOI":"10.1371\/journal.pone.0024895","volume":"6","author":"H Yan","year":"2011","unstructured":"Yan H, Xia M, Chang X, Xu Q, Bian H, Zeng M, et al. Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study. PLoS One. 2011;6:e24895.","journal-title":"PLoS One"},{"key":"786_CR30","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/MCO.0b013e328346a326","volume":"14","author":"S Kralisch","year":"2011","unstructured":"Kralisch S, Fasshauer M. Fibroblast growth factor 21: effects on carbohydrate and lipid metabolism in health and disease. Curr Opin Clin Nutr Metab Care. 2011;14:354\u20139.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"786_CR31","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","volume":"16","author":"L Geng","year":"2020","unstructured":"Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol. 2020;16:654\u201367.","journal-title":"Nat Rev Endocrinol"},{"key":"786_CR32","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","volume":"160","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, Group NCRRGW. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 2010;160:1577\u20139.","journal-title":"Br J Pharmacol"},{"key":"786_CR33","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nature11556","volume":"490","author":"SC Landis","year":"2012","unstructured":"Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490:187\u201391.","journal-title":"Nature."},{"key":"786_CR34","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.biochi.2012.10.019","volume":"95","author":"FG Schaap","year":"2013","unstructured":"Schaap FG, Kremer AE, Lamers WH, Jansen PL, Gaemers IC. Fibroblast growth factor 21 is induced by endoplasmic reticulum stress. Biochimie. 2013;95:692\u20139.","journal-title":"Biochimie."},{"key":"786_CR35","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/JOE-15-0160","volume":"226","author":"KH Kim","year":"2015","unstructured":"Kim KH, Lee MS. FGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs. J Endocrinol. 2015;226:R1\u201316.","journal-title":"J Endocrinol"},{"key":"786_CR36","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00125-014-3475-6","volume":"58","author":"SH Kim","year":"2015","unstructured":"Kim SH, Kim KH, Kim HK, Kim MJ, Back SH, Konishi M, et al. Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stress. Diabetologia. 2015;58:809\u201318.","journal-title":"Diabetologia."},{"key":"786_CR37","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1747-0285.2012.01325.x","volume":"79","author":"J Yie","year":"2012","unstructured":"Yie J, Wang W, Deng L, Tam LT, Stevens J, Chen MM, et al. Understanding the physical interactions in the FGF21\/FGFR\/beta-Klotho complex: structural requirements and implications in FGF21 signaling. Chem Biol drug Des. 2012;79:398\u2013410.","journal-title":"Chem Biol drug Des"},{"key":"786_CR38","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/jcp.21675","volume":"219","author":"R Micanovic","year":"2009","unstructured":"Micanovic R, Raches DW, Dunbar JD, Driver DA, Bina HA, Dickinson CD, et al. Different roles of N- and C- termini in the functional activity of FGF21. J Cell Physiol. 2009;219:227\u201334.","journal-title":"J Cell Physiol"},{"key":"786_CR39","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1053\/j.gastro.2010.04.054","volume":"139","author":"J Dushay","year":"2010","unstructured":"Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010;139:456\u201363.","journal-title":"Gastroenterology."},{"key":"786_CR40","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.2337\/db10-0193","volume":"59","author":"FM Fisher","year":"2010","unstructured":"Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010;59:2781\u20139.","journal-title":"Diabetes."},{"key":"786_CR41","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature01137","volume":"420","author":"J Hirosumi","year":"2002","unstructured":"Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, et al. A central role for JNK in obesity and insulin resistance. Nature. 2002;420:333\u20136.","journal-title":"Nature."},{"key":"786_CR42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s00125-010-1944-0","volume":"54","author":"J Jager","year":"2011","unstructured":"Jager J, Corcelle V, Gremeaux T, Laurent K, Waget A, Pages G, et al. Deficiency in the extracellular signal-regulated kinase 1 (ERK1) protects leptin-deficient mice from insulin resistance without affecting obesity. Diabetologia. 2011;54:180\u20139.","journal-title":"Diabetologia."},{"key":"786_CR43","doi-asserted-by":"publisher","first-page":"42731","DOI":"10.1074\/jbc.M506223200","volume":"280","author":"W Cao","year":"2005","unstructured":"Cao W, Collins QF, Becker TC, Robidoux J, Lupo EG Jr., Xiong Y, et al. p38 Mitogen-activated protein kinase plays a stimulatory role in hepatic gluconeogenesis. J Biol Chem. 2005;280:42731\u20137.","journal-title":"J Biol Chem"},{"key":"786_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04361-y","volume":"9","author":"J Bricambert","year":"2018","unstructured":"Bricambert J, Alves-Guerra MC, Esteves P, Prip-Buus C, Bertrand-Michel J, Guillou H, et al. The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity. Nat Commun. 2018;9:2092.","journal-title":"Nat Commun"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00786-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00786-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00786-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T20:52:08Z","timestamp":1725915128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00786-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["786"],"URL":"https:\/\/doi.org\/10.1038\/s41401-021-00786-2","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]},"assertion":[{"value":"14 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}